Bristol-Myers Squibb Co (BMY) : Lvm Capital Management Ltdmi reduced its stake in Bristol-Myers Squibb Co by 1.34% during the most recent quarter end. The investment management company now holds a total of 14,737 shares of Bristol-Myers Squibb Co which is valued at $972,347 after selling 200 shares in Bristol-Myers Squibb Co according to a report filed by the company on Apr 4, 2016 with the SEC.Bristol-Myers Squibb Co makes up approximately 0.31% of Lvm Capital Management Ltdmi’s portfolio.
Other Hedge Funds, Including , Pensionfund Dsm Netherlands added BMY to its portfolio by purchasing 95,000 company shares during the most recent quarter which is valued at $6.3 Million. Bristol-Myers Squibb Co makes up approx 0.85% of Pensionfund Dsm Netherlands’s portfolio. Beacon Financial Group sold out all of its stake in BMY during the most recent quarter. The investment firm sold 10,870 shares of BMY which is valued $705,572.
On the company’s financial health, Bristol-Myers Squibb Co reported $0.38 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jan 28, 2016. Analyst had a consensus of $0.28. The company had revenue of $4287.00 million for the quarter, compared to analysts expectations of $4154.19 million. The company’s revenue was up .7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.46 EPS.
Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Societe Generale Initiated Bristol-Myers Squibb Co on Apr 6, 2016 to “Sell”, Price Target of the shares are set at $48.Bristol-Myers Squibb Co was Upgraded by Berenberg to ” Buy” on Jan 22, 2016.
Bristol-Myers Squibb Co closed down -0.09 points or -0.14% at $65.98 with 35,45,773 shares getting traded on Monday. Post opening the session at $66.2, the shares hit an intraday low of $65.77 and an intraday high of $66.49 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.